Showing results (71-80 of 504) with videos related to
Sort By:
Pageof 51
Nephrology (Carlton, Vic.)|May 12, 2012
Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular riskNigel D Toussaint, Eugenie Pedagogos, Sven-Jean Tan, et al.BMJ (Clinical Research Ed.)|February 27, 2008
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trialsGiovanni F M Strippoli, Sankar D Navaneethan, David W Johnson, et al.Clinical Journal of the American Society of Nephrology : CJASN|June 5, 2019
Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical OutcomesToshiaki Ohkuma, Min Jun, John Chalmers, et al.Journal of the American College of Cardiology|September 3, 2011
Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysisSunil V Badve, Matthew A Roberts, Carmel M Hawley, et al.Journal of the American Society of Nephrology : JASN|May 1, 2010
Long-term cancer risk of immunosuppressive regimens after kidney transplantationMartin P Gallagher, Patrick J Kelly, Meg Jardine, et al.Diabetes, Obesity & Metabolism|July 22, 2020
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS ProgramDavid R Matthews, Carol Wysham, Melanie Davies, et al.Plos One|August 11, 2016
Effects of the Mediterranean Diet on Cardiovascular Outcomes-A Systematic Review and Meta-AnalysisThaminda Liyanage, Toshiharu Ninomiya, Amanda Wang, et al.Diabetes, Obesity & Metabolism|November 16, 2019
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS ProgramToshiaki Ohkuma, Luc Van Gaal, Wayne Shaw, et al.American Journal of Public Health|May 31, 2008
Socioeconomic disadvantage and kidney disease in the United States, Australia, and ThailandSarah L White, Kevin McGeechan, Michael Jones, et al.Journal of the American Geriatrics Society|March 19, 2025
The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE TrialsTu N Nguyen, Jie Yu, Vlado Perkovic, et al.Pageof 51